We could not find any results for:
Make sure your spelling is correct or try broadening your search.
GT Biopharma Inc is an immuno-oncology company operating in the United States. It is engaged in discovering, developing and commercializing novel therapeutics from its proprietary product platform in a varied range of disease areas. The company mainly develops drugs focused on the treatment of cance... GT Biopharma Inc is an immuno-oncology company operating in the United States. It is engaged in discovering, developing and commercializing novel therapeutics from its proprietary product platform in a varied range of disease areas. The company mainly develops drugs focused on the treatment of cancer. Its key drug candidates are OXS-2175, targeting the treatment of triple-negative breast cancer; OXS-4235, targets the treatment of multiple myeloma and associated osteolytic lesions; and OXS-1550, targets cancer cells expressing the CD19 receptor and CD22 receptor. Its TriKE and TetraKE platforms offer immuno-oncology products that can treat a range of hematologic malignancies, sarcoma, and solid tumors. Show more
false --12-31 0000109657 0000109657 2024-02-01 2024-02-01 iso4217:USD xbrli:shares iso4217:USD xbrli:shares ...
false 0000109657 0000109657 2023-12-18 2023-12-18 iso4217:USD xbrli:shares iso4217:USD xbrli:shares ...
false 0000109657 0000109657 2023-12-04 2023-12-04 iso4217:USD xbrli:shares iso4217:USD xbrli:shares ...
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the...
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) Proxy Statement Pursuant to...
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) Proxy Statement Pursuant to Section...
0000109657 false --12-31 Q3...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0.21 | 5.04807692308 | 4.16 | 5.21 | 3.81 | 34871 | 4.51722633 | CS |
4 | 0.02 | 0.459770114943 | 4.35 | 5.21 | 3.81 | 18034 | 4.64918707 | CS |
12 | -3.43 | -43.9743589744 | 7.8 | 7.803 | 3.52 | 72114 | 6.23472991 | CS |
26 | -2.998 | -40.6894679696 | 7.368 | 9.9 | 3.52 | 98432 | 6.98315755 | CS |
52 | -13.63 | -75.7222222222 | 18 | 18 | 3.52 | 241671 | 8.910551 | CS |
156 | -205.63 | -97.919047619 | 210 | 591.993 | 3.52 | 235777 | 152.28553192 | CS |
260 | -160.63 | -97.3515151515 | 165 | 591.993 | 3.52 | 251241 | 154.45544796 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions